AstraZeneca Plc (AZ), the Finnish-Swedish global pharmaceutical company, is working with US sequencing specialist Human Longevity, the UK’s Wellcome Trust Sanger Institute and the Finland Institute for Molecular Medicine (FIMM) to launch a genomics initiative for drug discovery. A total of 500,000 clinical trials samples will be collected and a new Genomics Research Centre is to be set up for examining around two million genome sequences. Human Longevity intends to use machine learning to analyse clinical trial samples, AZ and the Sanger Institute aim to identify new biomarkers and drug targets, and FIMM will study genes of relevance in the British population. AZ’s use of big data analysis for mining genome sequences to discover unknown molecular pathways, and other medical insights, forms part of the UK’s 100,000 Genomes Project by Genomics England. This project maps the DNA of cancer patients and those with rare genetic conditions for anonymised data linkage with NHS records.
AstraZeneca Plc (AZ), the British-Swedish global pharmaceutical company, is working with US sequencing specialist Human Longevity, the UK’s Wellcome Trust Sanger Institute and the Finland Institute for Molecular Medicine (FIMM) to launch a genomics initiative for drug discovery. A total of 500,000 clinical trials samples will be collected and a new Genomics Research Centre is to be set up for examining around two million genome sequences. Human Longevity intends to use machine learning to analyse clinical trial samples, AZ and the Sanger Institute aim to identify new biomarkers and drug targets, and FIMM will study genes of relevance in the Finnish population. AZ’s use of big data analysis for mining genome sequences to discover unknown molecular pathways, and other medical insights, forms part of the UK’s 100,000 Genomes Project by Genomics England. This project maps the DNA of cancer patients and those with rare genetic conditions for anonymised data linkage with NHS records.